Obesity-driven gut-immune-brain axis dysregulation: Emerging molecular targets and biomaterial-based interventions

Obesity Medicine · Published 2026-07-15 · DOI 10.1016/j.obmed.2026.100731

Authors (15)

Nazmul MHM, Vetriselvan Subramaniyan, Srikumar Chakravarthi, Thidar Aung, Sergey Gupalo, Wana Hla Shwe, Sutha Devaraj, Phone Myint Htoo, Myat Myo Naing, Lei Lei Win, Aye Aye Tun, Tahmina Afrose Keya, Srikanth Jeyabalan, Chetan Ashok, Mukesh Kumar

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

MHM, N., Subramaniyan, V., Chakravarthi, S., et al. (2026). Obesity-driven gut-immune-brain axis dysregulation: Emerging molecular targets and biomaterial-based interventions. Obesity Medicine. https://doi.org/10.1016/j.obmed.2026.100731

Related articles

• Multidimensional cardiometabolic protection with SGLT2 inhibitors and GLP-1 receptor agonists in obesity, type 2 diabetes and hypertension · Obesity Medicine · 2026 · Same journal
• Rethinking obesity metrics: Cytokines and insulin resistance a better cardiometabolic risk predictor than BMI in young Indian adults · Obesity Medicine · 2026 · Same journal
• Microbiota–gut–brain axis dysregulation in obesity: Neuroimmune-endocrine mechanisms and precision therapeutic targets · Obesity Medicine · 2026 · Same journal
• Nanoformulations for obesity-driven MASLD and MASH: Cell-specific hepatic drug delivery, comorbidity outcomes, and translational perspectives · Obesity Medicine · 2026 · Same journal
• Advances in GLP-1 receptor agonists: Molecular mechanisms, drug delivery innovations, formulation strategies, and emerging therapeutic applications · Obesity Medicine · 2026 · Same journal
• Improving obesity risk stratification across Asian and European populations: A clinical imperative · Obesity Medicine · 2026 · Same journal
• Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study · Obesity Medicine · 2025 · Same journal
• Nanotechnology-enabled targeted delivery of incretin therapies for the treatment of obesity and metabolic disorders · Obesity Medicine · 2026 · Same journal
• Optimizing post-bariatric surgery weight management: The role of semaglutide · Obesity Medicine · 2025 · Same journal
• The underestimated axis: Enteroendocrine-Microbiota interactions in obesity pathogenesis and therapy · Obesity Medicine · 2025 · Same journal